Extracted from this filing and checked against the source text.
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
Genprex, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).
- Exchange
- nasdaq
- Notice
- compliance regained
- Deficiency
- minimum bid price
- Rules
- 5550(a)(2)
Exact text from the filing
November 25, 2025, the Company was formally notified that (i) the Panel determined that the Company has regained compliance with the Bid Price Requirement; and (ii) the Panel has also approved the Company’s request for an exception until December 31, 2025 to demonstrate long-term compliance with the Stockholders’ Equity Requirement (as extended, the “Exception”). As previously disclosed, upon request by the Company, the Panel has discretion to grant the Company continued listing through February 9, 2026. Pursuant to the Exception, the Company is required to, and fully intends to, provide the
View on SEC.gov
Listing & Compliance Notices
SEC 8-K Item 3.01
confidence 0.9
Genprex, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).
- Exchange
- nasdaq
- Notice
- extension granted
- Deficiency
- stockholders equity
- Rules
- 5550(b)(1)
Exact text from the filing
November 25, 2025, the Company was formally notified that (i) the Panel determined that the Company has regained compliance with the Bid Price Requirement; and (ii) the Panel has also approved the Company’s request for an exception until December 31, 2025 to demonstrate long-term compliance with the Stockholders’ Equity Requirement (as extended, the “Exception”). As previously disclosed, upon request by the Company, the Panel has discretion to grant the Company continued listing through February 9, 2026. Pursuant to the Exception, the Company is required to, and fully intends to, provide the
View on SEC.gov